Alan Bash Joins Legend Biotech As President Of CARVYKTI®, Driving Commercial Growth
Legend Biotech appoints Alan Bash as President of CARVYKTI®, overseeing its growth and operations.
Breaking News
Nov 05, 2024
Simantini Singh Deo

Legend Biotech Corporation, a cell therapy leader, announces Alan Bash as the new President of CARVYKTI®. In this position, he will oversee the continued growth of CARVYKTI®, leading commercial operations, technical functions, and quality control for the CARVYKTI® franchise.
Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech, said in a statement, “This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in treating multiple myeloma.”
Mr. Bash has significant experience in oncology, having served most recently as CEO of ZielBio and, prior to that, as President and Chief Executive Officer of Checkmate Pharmaceuticals. He also spent 23 years at Bristol Myers Squibb in various roles, including launching Opdivo® in the U.S. market and growing significant treatments for cancer like Yervoy® and Erbitux®. He has worked on phenomenal collaborations such as Abilify® with Otsuka and Eliquis® with Pfizer.
Mr. Bash holds a B.A. from Georgetown University and an M.B.A. from Columbia Business School.
Mr. Alan Bash also mentioned, “As the fastest-launched CAR-T product on the market, CARVYKTI has already produced impressive momentum. I am excited about the opportunity to support the continued success of the CARVYKTI franchise and work with the Legend Biotech team and our collaboration partner, Johnson & Johnson, to fulfill CARVYKTI’s potential to transform the treatment paradigm for multiple myeloma.”